Ann: Investor Presentation, page-108

  1. 924 Posts.
    lightbulb Created with Sketch. 440
    Sydney 26th May 2023: Nyrada Inc (ASX: NYR), a preclinical stage, drug development company
    specialising in novel small molecule drugs to treat cardiovascular and neurological diseases, is
    pleased to announce all of the preclinical Good Laboratory Practice (GLP) studies required by
    the regulators to evaluate the safety and tolerability of its cholesterol-lowering drug candidate
    were successfully completed at the end of April. The Company is on track to commence its
    Phase I/IIa first-in-human study in early 2H CY2023.

    Benny Boy, the cholesterol drug had completed all GLP studies!
    It was past the point that NYR-BIO3 is currently at when it got pulled up.
    I thought you said we had proven safety?!?!
    Maybe they used lactose intolerant mice in the cholesterol studies? Can mice even be lactose intolerant?

 
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)
Last
30.0¢
Change
0.000(0.00%)
Mkt cap ! $63.43M
Open High Low Value Volume
30.0¢ 30.0¢ 29.0¢ $245.6K 829.7K

Buyers (Bids)

No. Vol. Price($)
2 29101 29.5¢
 

Sellers (Offers)

Price($) Vol. No.
30.0¢ 311729 2
View Market Depth
Last trade - 16.10pm 08/08/2025 (20 minute delay) ?
NYR (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.